emavusertib — Topline data
Dec 2026
Curis expects to announce the dosing of the initial 5 patients in the TakeAim CLL combination study with zanubrutinib by mid-2026, with data expected in December 2026.Source filing
CRIS biotech catalysts & pipeline
CURIS INC · Data as of 2026-09-08
Upcoming catalysts
emavusertib — Topline data
H1 2027
Also, the Company expects updated emavusertib clinical data from the TakeAim Lymphoma combination study with ibrutinib in patients with R/R PCNSL in the first half of 2027.Source filing
emavusertib — Conference presentation
Dec 12–Dec 15
and, finally, we have filed the protocol with the FDA for our Phase 2 study of emavusertib + BTKi in CLL, we are working to activate clinical sites, and we expect to enroll our first patient in late Q4 or early Q1, with data expected at the ASH annual meeting in December 2026.Source filing